Mounjaro NHS Criteria - Guide | Cured Pharmacy

Mounjaro NHS Criteria

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From £145.00£124.99UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 22 June 2026

Last Updated: 12 August 2026

If you have been hearing about Mounjaro and wondering whether you might be eligible to get it on the NHS, you are not alone. Thousands of people across the UK are asking the same question, and unfortunately, the answer is not always straightforward. The NHS has specific eligibility requirements for Mounjaro, and many people who could genuinely benefit from it find themselves falling just outside the criteria — leaving them confused, frustrated, and unsure where to turn next. This guide breaks down exactly what the Mounjaro NHS criteria involve, who qualifies, who does not, and what your options are if the NHS route is not available to you right now.

Quick Summary

Mounjaro (tirzepatide) is one of the most effective weight loss medications available in the UK, but NHS access is restricted to those who meet very specific clinical thresholds. If you are not sure whether you qualify or what to do if you do not, this guide covers everything you need to know clearly and practically.

  • Mounjaro is currently available on the NHS only through specialist weight management services, not via your GP
  • You must have a BMI of 35 or above, plus at least one weight-related health condition, to meet the core criteria
  • People of South Asian, Chinese, or other high-risk ethnic backgrounds may qualify at a lower BMI threshold
  • NHS access is being rolled out in phases and waiting lists can be lengthy in many parts of England
  • Private prescription options exist for those who do not meet the NHS criteria or who cannot wait for an appointment

Mounjaro NHS Eligibility Checker

Answer a few quick questions to see whether you may meet the NHS criteria. This is a guide only — always speak to a clinician for a full assessment.

Table of Contents

  1. What Is Mounjaro and Why Is Everyone Talking About It?
  2. Mounjaro NHS Criteria Explained in Plain English
  3. Who Does Not Qualify and What Are the Exclusions?
  4. How to Get Referred Through the NHS
  5. NHS vs Private Prescription: What Is the Difference?
  6. Full Eligibility Criteria at a Glance
  7. Key Takeaways
  8. When to Seek Professional Advice
  9. Scientific References
  10. Frequently Asked Questions

What Is Mounjaro and Why Is Everyone Talking About It?

Mounjaro is the brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist that was originally developed to treat type 2 diabetes and has since been licensed in the UK for chronic weight management. Unlike older weight loss medications, tirzepatide works on two separate hormonal pathways simultaneously — suppressing appetite, slowing gastric emptying, and improving insulin sensitivity all at once. The results from clinical trials have been genuinely remarkable, with participants losing an average of 20% or more of their body weight in some studies. It is no surprise that demand for Mounjaro NHS criteria information has surged as people try to understand whether they can access it. Understanding the Mounjaro NHS criteria is the first practical step for anyone considering this treatment.

Tirzepatide received its MHRA licence in the UK in November 2023, and NICE subsequently issued guidance recommending its use within NHS specialist weight management services. However, the rollout has been phased and complex. Unlike Orlistat weight loss capsules, which are available more broadly, Mounjaro sits in a higher-tier treatment category — meaning access through the NHS comes with clearly defined gatekeeping criteria.

  • Mounjaro is a dual GIP and GLP-1 receptor agonist — a new class of weight management medicine
  • NICE approved it for NHS use in specialist weight management settings in 2023
  • Clinical trials show average weight loss of between 15% and 22.5% of body weight over 72 weeks
  • It is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen
  • NHS access is being rolled out in phases, with specialist services prioritised first

Mounjaro NHS Criteria Explained in Plain English

The Mounjaro NHS criteria are set out in NICE technology appraisal guidance TA1026. To be eligible, patients must be seen within a specialist weight management service — this means you cannot simply ask your GP to prescribe it directly. The core eligibility thresholds are a BMI of 35 kg/m² or above combined with at least one weight-related comorbidity. Weight-related comorbidities that count include type 2 diabetes, hypertension, obstructive sleep apnoea, dyslipidaemia, cardiovascular disease, and non-alcoholic fatty liver disease. These conditions must be documented and clinically confirmed.

For patients from certain ethnic backgrounds, the BMI threshold is adjusted downward to reflect the fact that people of South Asian, Chinese, Middle Eastern, Black African, and African-Caribbean descent experience greater cardiometabolic risk at lower BMI values. In these populations, a BMI of 32.5 kg/m² or above with a relevant comorbidity may be sufficient to meet the Mounjaro NHS criteria. This adjustment is important and often overlooked during self-assessment, so it is worth raising with your GP if it applies to you. It is worth noting that in 2026, NHS England continues to refine how these ethnic adjustments are applied across Integrated Care Boards (ICBs).

  • BMI threshold: 35 kg/m² or above for most patients
  • Adjusted threshold: 32.5 kg/m² or above for high-risk ethnic backgrounds
  • At least one weight-related comorbidity must be present and documented
  • Treatment must be initiated and supervised within an NHS specialist weight management service
  • Patients must have received or attempted lifestyle interventions prior to starting medication
  • Mounjaro is not available directly from a GP surgery under the NHS pathway

It is also worth understanding that Mounjaro NHS criteria include a requirement for patients to have engaged with non-pharmacological weight management support, such as behavioural interventions or structured dietary programmes. Essentially, the NHS wants to see evidence that a patient has tried other approaches before escalating to medication. This is consistent with NICE's stepped-care approach to obesity management.

Who Does Not Qualify and What Are the Exclusions?

Even if your BMI appears to fall within range, there are a number of clinical exclusions that would prevent a prescriber from offering Mounjaro. People who are pregnant or breastfeeding are excluded, as tirzepatide has not been studied in these populations and potential risks to the foetus or infant are unknown. Similarly, Mounjaro is not suitable for individuals with a personal or family history of medullary thyroid carcinoma, or for those with Multiple Endocrine Neoplasia type 2 (MEN2). These are precautionary exclusions based on findings from animal studies.

People with severe gastroparesis, active eating disorders (such as anorexia nervosa or bulimia), or active inflammatory bowel disease may also be excluded on clinical grounds. Those with a history of acute pancreatitis should be assessed carefully before being considered, as GLP-1 receptor agonists have been associated with an increased risk of pancreatic inflammation in some patients. The Mounjaro NHS criteria also exclude patients who are already achieving adequate weight loss through other means.

  • Pregnancy or breastfeeding — absolute contraindication
  • Personal or family history of medullary thyroid carcinoma or MEN2
  • Severe, uncontrolled gastroparesis
  • Active and untreated eating disorders
  • Severe renal impairment (eGFR below 15 ml/min/1.73m²) — use with caution and specialist guidance
  • Patients under 18 years of age — not currently licensed for this age group for weight management

Another common reason people fall outside the Mounjaro NHS criteria is simply not being able to access a specialist weight management service. These services are not uniformly distributed across England, and waiting times vary enormously. In some regions, waiting lists stretch to 12 months or longer. This practical barrier — rather than a clinical one — affects a huge number of people who technically would meet the eligibility thresholds. If you are in this situation, understanding your alternatives becomes essential.

How to Get Referred Through the NHS

If you believe you meet the Mounjaro NHS criteria, the first step is to speak with your GP. Your GP cannot prescribe Mounjaro directly, but they can refer you to a specialist weight management service (also known as a Tier 3 or Tier 4 weight management service). During this referral process, your GP will review your BMI, existing health conditions, and any prior attempts at weight management. They may ask you to complete a structured weight management programme before submitting the referral, depending on your local ICB's specific requirements.

Once referred, you will be assessed by a multidisciplinary team that typically includes a dietitian, a psychologist, and a physician. This team will determine whether Mounjaro is appropriate for you, taking into account your full medical history, medication list, and weight loss goals. If approved, treatment is usually initiated at the 2.5mg dose once weekly and escalated gradually over several months. It is important to approach your GP appointment prepared — bring details of any weight-related conditions you have been diagnosed with, evidence of previous lifestyle interventions, and any relevant blood test results.

  • Book an appointment with your GP and specifically mention Mounjaro and NICE TA1026
  • Ask for a referral to your local Tier 3 specialist weight management service
  • Gather evidence of previous weight management attempts (e.g. slimming club records, GP notes)
  • Have your most recent blood pressure, HbA1c, and lipid results to hand if available
  • Be prepared for a waiting period — many services have significant backlogs in 2026

If your GP is unfamiliar with the NICE guidance or seems reluctant to refer, you are entitled to request a second opinion or to ask to see a different GP within the practice. Patient advocacy can make a real difference here. Some people also find it helpful to print a copy of NICE TA1026 guidance and bring it to the appointment as a reference point.

NHS vs Private Prescription: What Is the Difference in Practice?

If you do not meet the Mounjaro NHS criteria or face a lengthy wait, a private prescription is a legitimate and increasingly popular alternative. Private prescribers, including registered online pharmacies, can assess your eligibility independently using clinically appropriate criteria. Private criteria typically include a lower BMI threshold — often 30 kg/m² or above with a comorbidity, or 27 kg/m² or above for those with a weight-related health condition and higher-risk ethnic background — making it accessible to a broader group of patients.

The cost of Mounjaro privately varies depending on the dose and the provider. At Cured Pharmacy, Mounjaro is available from From £145.00£124.99 with a free private prescription following a short online assessment completed by a UK-based prescribing pharmacist. All prescriptions are reviewed by GPhC-registered professionals, and the medication is dispatched in discreet packaging. For people who want effective treatment without waiting months for an NHS appointment, this can be a genuinely viable and safe route. You may also wish to explore Alli weight loss capsules as a supplementary option alongside lifestyle changes if injectable medications are not yet suitable for you.

  • Private prescriptions allow access to Mounjaro without an NHS specialist referral
  • Private eligibility criteria are often slightly broader than NHS thresholds
  • The online assessment typically takes under 5 minutes and is reviewed by a UK prescriber
  • Mounjaro is delivered discreetly and directly to your home
  • Private access does not affect your right to seek NHS treatment in future
  • Regular monitoring and follow-up support should be included as part of any private prescription service

For those who want to support their weight management journey holistically, products like XLS Medical Weight Loss Plus tablets can complement dietary changes while you wait for or continue alongside Mounjaro treatment. Similarly, XLS Medical Direct Fat Binder sachets offer an additional non-prescription approach to reducing calorie absorption from dietary fat.

Full Mounjaro Eligibility Criteria at a Glance

Criterion NHS Requirement Typical Private Requirement
Minimum BMI (standard) 35 kg/m² or above 30 kg/m² or above
Minimum BMI (high-risk ethnic groups) 32.5 kg/m² or above 27.5 kg/m² or above
Weight-related comorbidity required Yes — at least one documented Yes for lower BMI thresholds
Prior lifestyle intervention required Yes — evidence required Recommended but not always mandatory
Prescriber type NHS specialist weight management service only GPhC-registered prescriber or private clinic
Waiting time Several months to over a year in many areas Often within 24–48 hours
Cost to patient Standard NHS prescription charge (£9.90 per item in 2026) From £145 per month privately
Ongoing monitoring included Yes — multidisciplinary team Varies by provider — should be included
Pregnancy / breastfeeding Excluded Excluded
History of medullary thyroid carcinoma / MEN2 Excluded Excluded

Key Takeaways

  • The Mounjaro NHS criteria require a BMI of at least 35 kg/m² (or 32.5 kg/m² for high-risk ethnic groups) plus a documented weight-related comorbidity
  • NHS access is through specialist weight management services only — your GP cannot prescribe it directly
  • Waiting times across England can be significant, particularly in 2026, making private prescription a practical alternative for many
  • Clinical exclusions include pregnancy, history of medullary thyroid cancer, MEN2, and severe gastroparesis
  • Private prescription services offer faster access with a lower BMI threshold and can be a safe, clinically supervised option

When to Seek Professional Advice

You should speak to a healthcare professional if you are unsure whether you meet the Mounjaro NHS criteria, if you have a complex medical history, or if you are currently taking medications that may interact with tirzepatide. This is especially important if you are using insulin or sulfonylureas for diabetes management, as combining these with Mounjaro may increase hypoglycaemia risk. Always consult a qualified prescriber before starting any weight management medication.

Seek urgent medical advice if you experience severe abdominal pain after starting Mounjaro, which could indicate pancreatitis, or if you notice a rapidly growing neck mass or persistent hoarseness, which — while rare — could signal a thyroid concern. You should also speak to a clinician if you are struggling with nausea, vomiting, or dehydration following dose escalation, as dose adjustments may be needed. Regular check-ins with your prescriber are essential throughout your treatment course.

Scientific References

  1. National Institute for Health and Care Excellence (NICE). Tirzepatide for managing overweight and obesity. Technology appraisal guidance TA1026. NICE, 2023. [Accessed 12 August 2026]
  2. NHS England. Policy for the use of tirzepatide (Mounjaro) for the management of obesity in adults. NHS England, 2024. [Accessed 12 August 2026]
  3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216. (SURMOUNT-1 trial). [Accessed 12 August 2026]
  4. NICE Technology Appraisal TA924: Tirzepatide for managing overweight and obesity, NICE, 2024 [Accessed 12 August 2026]
  5. NICE Guideline NG28: Type 2 diabetes in adults: management, NICE, 2022 (updated) [Accessed 12 August 2026]
  6. NHS England Implementation Guidance for Tirzepatide (Mounjaro) for Weight Management, NHS England, 2024 [Accessed 12 August 2026]
  7. Mounjaro (tirzepatide) Summary of Product Characteristics, Eli Lilly, Electronic Medicines Compendium (EMC), 2023 [Accessed 12 August 2026]
  8. Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022 [Accessed 12 August 2026]
  9. Diabetes UK Position Statement: Treatment Targets in Type 2 Diabetes, Diabetes UK, 2023 [Accessed 12 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My Assessment Returning Customer? Log In to Your Account

Frequently Asked Questions

How long does it take to get Mounjaro on the NHS?

Getting Mounjaro on the NHS typically takes several months, as you must first be referred to a specialist weight management service, complete an assessment, and then be placed on a waiting list. Waiting times vary significantly by region, with some areas waiting six months to over a year in 2026.

Is Mounjaro safe to use for weight loss long-term?

Mounjaro is considered safe for long-term use when prescribed and monitored by a qualified healthcare professional. Clinical trials including the SURMOUNT studies demonstrated that tirzepatide was well tolerated over 72 weeks, with the most common side effects being mild to moderate gastrointestinal symptoms such as nausea and diarrhoea.

Can you take Mounjaro with other diabetes medications?

Mounjaro can be taken alongside certain diabetes medications, but combining it with insulin or sulfonylureas may increase the risk of hypoglycaemia. Your prescriber will review your full medication list before prescribing tirzepatide to ensure it is safe and appropriate for your individual circumstances and health conditions.

What is the starting dose of Mounjaro for weight loss?

The starting dose of Mounjaro for weight loss is 2.5mg once weekly, injected subcutaneously. After four weeks, the dose is typically increased to 5mg weekly, with further dose escalations every four weeks as tolerated, up to a maximum maintenance dose of 15mg per week depending on your response and tolerability.

Back to blog